EUCTR2007-001691-36-AT进行中（未招募）不适用
A Multicenter, Double-Blind, Randomized, Placebo and Active Comparator Controlled Dose Range Finding Study in MK-0893 in Patients with Type 2 Diabetes Mellitus Who Have Indequate Glycemic Control. - A dose-range finding study for MK-0893
Merck Sharp & Dohme GmbH0 个研究点目标入组 727 人开始时间: 2007年7月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 727
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a.Patient has T2DM.
- •b.Patient is =21 and =70 years of age on day of signing the informed consent form.
- •c.Patient is either
- •Not on oral antihyperglycemic medications for at least 10 weeks, with an HbA1c of =7.0% and =11.0%, OR
- •On a single oral antihyperglycemic medication (but not on a PPAR-? agonist), with an HbA1c of =6.5% and =10.0%, OR
- •On a low-dose combination oral antihyperglycemic medication at a dose less than or equal to 50% of the maximum recommended dose of both components, with an HbA1c of =6.5% and =10.0%.
- •d.Patient is a male, or a female who is unlikely to conceive, as indicated by at least one yes” answer to the following questions:
- •1)Patient is a male.
- •2)Patient is a surgically sterilized female.
- •3)Patient is a postmenopausal female =45 years of age with >2 years since last menses.
- •4)Patient is a non-sterilized, premenopausal female and agrees to: (1) use 2 adequate methods of contraception to prevent pregnancy (2 barrier methods) or abstain from heterosexual activity throughout the study starting with Visit 1/ Screening and for 28 days after the last dose of study medication.
- •Note: Acceptable methods of birth control are: intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, or vasectomy. See Appendix 6.13 for details.
- •e.Patient understands the study procedures, alternative treatments available, and risks involved with the study, and voluntarily agrees to participate by giving informed written consent.
- •At Visit 3/Week -2
- •f.Patient has a HbA1c of =7.0% and =11.0%.
- •At Visit 4/Day -1/Randomization
- •g.Patient has = 85% compliance with placebo treatment during the single-blind run-in as measured by site-performed tablet count.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a.Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis.
- •Patient is assessed by the investigator as possibly having type 1 diabetes confirmed with a C-peptide <0.7 ng/mL (0.23 nmol/L).
- •b.Patient has symptomatic hyperglycemia requiring immediate initiation or addition of antihyperglycemic therapy.
- •c.Patient has been treated with a PPAR-? agonist within the past 3 months.
- •d.Patient has been treated with insulin within the past 2 months.
- •e.Patient has been treated with a GLP-1 mimetic or agonist within the past 2 months.
- •f.Patient has a history of hypersensitivity or contraindication to metformin.
- •g.Patient is on a weight loss program and is not in the maintenance phase, or patient has been treated with a weight loss medication within 8 weeks of Visit 1.
- •h.Patient has received treatment with an investigational drug within the prior 3 months or is participating in another clinical trial.
- •i.Patient is on or likely to require treatment with immunosuppressive/ immunomodulating agents or patient is on or likely to require treatment of =14 consecutive days or repeated courses of pharmacologic doses of corticosteroids.
- •j.Patient has undergone surgery within 30 days prior to Visit 1 or has planned major surgery.
- •k.Patient has new or worsening signs or symptoms of coronary heart disease or congestive heart failure within the past 3 months, or has any of the following disorders within the past 6 months:
- •acute coronary syndrome
- •coronary artery intervention
- •l.Patient has had a stroke or TIA
- •m.Patient has NYHA Class I - IV cardiac status
- •n.Patient has a systolic blood pressure of >150 mm Hg or diastolic blood pressure of >85 mm Hg.
- •o.Patient has severe peripheral vascular disease, active liver disease, or active nephropathy
- •p.Patient is HIV positive (as assessed by medical history).
- •q.Patient has a clinically significant hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia).
- •r.Patient is under treatment for hyperthyroidism.
- •s.Patient has a history of malignancy.
- •Exception: (1) patients with adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix may participate; (2) patients with other malignancies which have been successfully treated =5 years prior to screening, where in the judgment of both the investigator and treating physician, appropriate follow-up has revealed no evidence of recurrence from the time of treatment through the time of screening; and (3) patients who, in the joint opinion of the Merck medical monitor and investigator, are highly unlikely to sustain a recurrence during the duration of the study. However, patients with a history of leukemia, lymphoma, malignant melanoma, myeloproliferative disease or renal cell carcinoma are ineligible for the study regardless of the time since treatment, and in such cases, no exceptions will apply.
- •t.Patient is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence.
- •u. Patient does not agree to abstain from alcohol for 48 hours prior to each clinic visit.
- •v.Patient has donated blood products or has had phlebotomy of >300 mL within 8 weeks of signing informed consent, or intends to donate blood products or receive blood products within the projected duration of the study.
- •w.Patient is pregnant, has a positive urine preg
研究者
相似试验
进行中（未招募）
1 期
A Multicenter, Double-Blind, Randomized, Placebo and Active Comparator Controlled Dose Range Finding Study in MK-0893 in Patients with Type 2 Diabetes Mellitus Who Have Indequate Glycemic Control. - A dose-range finding study for MK-0893MedDRA version: 9.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitusType 2 Diabetes MellitusEUCTR2007-001691-36-HUMerck & Co., Inc.750
未知
不适用
Dose-Range Finding Study for MK0893 (0893-008)-E119 Non-insulin-dependent diabetes mellitus, without complicationsNon-insulin-dependent diabetes mellitus, without complicationsE119PER-041-07MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
不适用
A Multicenter, Double-Blind, Randomized, Placebo and Active Comparator Controlled Dose Range Finding Study in MK-0893 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control. - A dose-range finding study for MK-0893MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusType 2 Diabetes MellitusEUCTR2007-001691-36-DEMerck & Co., Inc.750
进行中（未招募）
不适用
A Study Comparing the Safety and Analgesic Efficacy of ABT-110 inSubjects with Pain from Osteoarthritis of the KneePain from Osteoarthritis of the KneeMedDRA version: 14.0Level: LLTClassification code 10031165Term: Osteoarthritis kneeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2011-002144-27-NLAbbott GmbH & Co. KG390
进行中（未招募）
不适用
A Study Comparing the Safety and Analgesic Efficacy of ABT-110 inSubjects with Pain from Osteoarthritis of the KneeEUCTR2011-002144-27-PLAbbVie Deutschland GmbH & Co. KG350